Research and Markets: T-Cell Leukemia - Pipeline Review, H2 2012 Out Now

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pdwrg8/tcell_leukemia) has announced the addition of Global Markets Direct's new report "T-Cell Leukemia - Pipeline Review, H2 2012" to their offering.

“T-Cell Leukemia - Pipeline Review, H2 2012”

Global Markets Direct's, 'T-Cell Leukemia - Pipeline Review, H2 2012', provides an overview of the T-Cell Leukemia therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Leukemia. 'T-Cell Leukemia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for T-Cell Leukemia.

- A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the T-Cell Leukemia pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/pdwrg8/tcell_leukemia

Source: Global Markets Direct